国际口腔医学杂志 ›› 2017, Vol. 44 ›› Issue (3): 325-331.doi: 10.7518/gjkq.2017.03.015

• 综述 • 上一篇    下一篇

口腔黏膜下纤维性变的药物治疗进展

刘锦丽, 陈方曼, 江潞   

  1. 口腔疾病研究国家重点实验室,国家口腔疾病临床医学研究中心,四川大学华西口腔医院黏膜科 成都 610041
  • 收稿日期:2016-07-15 修回日期:2017-01-16 出版日期:2017-05-01 发布日期:2017-05-01
  • 通讯作者: 江潞,副教授,博士,Email:jianglu@scu.edu.cn
  • 作者简介:刘锦丽,硕士,Email:524705510@qq.com
  • 基金资助:
    国家自然科学基金面上项目(81670998)

Drug management of oral submucous fibrosis

Liu Jinli, Chen Fangman, Jiang Lu.   

  1. State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2016-07-15 Revised:2017-01-16 Online:2017-05-01 Published:2017-05-01
  • Supported by:
    This study was supported by the National Natural Science Foundation of China(81670998).

摘要: 由于口腔黏膜下纤维性变(OSF)发病机制复杂,目前尚缺乏特效治疗手段,主要治疗方式仍为药物治疗。本文回顾介绍了近年来国内外临床上治疗OSF的药物种类,并主张根据疾病的病程选择不同的药物治疗。

关键词: 口腔黏膜下纤维性变, 药物, 治疗进展

Abstract: As the pathogenesis of oral submucons fibrosis is obscure, this disease is still lack of unified treatment. Drug management remains the major treatment plan. This paper summarizes a wide range of drug management which have been attempted till date, and claims to use different drug depending on the stage of the disease.

Key words: oral submucous fibrosis, drug, treatment progress

中图分类号: 

  • R781.5+9
[1] Singh M, Niranjan HS, Mehrotra R, et al. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcino-lone acetonide/hyaluronidase in the treatment of oral submucous fibrosis[J]. Indian J Med Res, 2010, 131(5):665-669.
[2] Kiran Kumar K, Saraswathi TR, Ranganathan K, et al. Oral submucous fibrosis: a clinico-histopathological study in Chennai[J]. Indian J Dent Res, 2007, 18(3): 106-111.
[3] Haque MF, Meghji S, Nazir R, et al. Interferon gamma(IFN-γ) may reverse oral submucous fibrosis [J]. J Oral Pathol Med, 2001, 30(1):12-21.
[4] Golay A, Ferrara JM, Felber JP, et al. Cholesterol-lowering effect of skim milk from immunized cows in hypercholesterolemic patients[J]. Am J Clin Nutr, 1990, 52(6):1014-1019.
[5] Tai YS, Liu BY, Wang JT, et al. Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements of symp-toms and signs in patients with oral submucous fib-rosis[J]. J Oral Pathol Med, 2001, 30(10):618-625.
[6] Jirge V, Shashikanth MC, Ali IM, et al. Levamisole and antioxidants in the management of oral submu-cous fibrosis: a comparative study[J]. J Indian Acad Oral Med Radiol, 2008, 20(4):135.
[7] Lin HJ, Lin JC. Treatment of oral submucous fibro-sis by collagenase: effects on oral opening and eating function[J]. Oral Dis, 2007, 13(4):407-413.
[8] Kakar PK, Puri RK, Venkatachalam VP. Oral sub-mucous fibrosis—treatment with hyalase[J]. J Laryn-gol Otol, 1985, 99(1):57-59.
[9] Auluck A, Rosin MP, Zhang L, et al. Oral submucous fibrosis, a clinically benign but potentially malignant disease: report of 3 cases and review of the literature [J]. J Can Dent Assoc, 2008, 74(8):735-740.
[10] Pineda AM, Tianco EA, Tan JB, et al. Oral pentoxi-fylline and topical clobetasol propionate ointment in the treatment of pretibial myxoedema, with concomi-tant improvement of Graves’ ophthalmopathy[J]. J Eur Acad Dermatol Venereol, 2007, 21(10):1441- 1443.
[11] Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral sub-mucous fibrosis[J]. Indian J Dent Res, 2007, 17(4): 190-198.
[12] Patil S, Maheshwari S. Efficacy of pentoxifylline in the management of oral submucous fibrosis[J]. J Orofac Sci, 2014, 6(2):94.
[13] Lai DR, Chen HR, Lin LM, et al. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases[J]. J Oral Pathol Med, 1995, 24(9):402-406.
[14] Sharma JK, Gupta AK, Mukhija RD, et al. Clinical experience with the use of peripheral vasodilator in oral disorders[J]. Int J Oral Maxillofac Surg, 1987, 16(6):695-699.
[15] Bhadage CJ, Umarji HR, Shah K, et al. Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis[J]. Clin Oral Investig, 2013, 17(5):1375- 1382.
[16] Chole RH, Gondivkar SM, Gadbail AR, et al. Review of drug treatment of oral submucous fibrosis[J]. Oral Oncol, 2012, 48(5):393-398.
[17] Maher R, Aga P, Johnson NW, et al. Evaluation of multiple micronutrient supplementation in the mana-gement of oral submucous fibrosis in Karachi, Pakis-tan[J]. Nutr Cancer, 1997, 27(1):41-47.
[18] Dhariwal R, Mukherjee S, Mohanty SP, et al. Zinc and vitamin A can minimise the severity of oral submucous fibrosis[J]. BMJ Case Rep, 2010, 2010:bcr1020092348.
[19] Kumar A, Bagewadi A, Keluskar V, et al. Efficacy of lycopene in the management of oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 103(2):207-213.
[20] Biswas G, Anup N, Kumawat H. Efficacy of lyco-pene in the management of oral submucous fib-rosis—a randomized clinical trial[J]. Indian J Public Health Res Development, 2015, 6(3):33-37.
[21] Mathew B, Sankaranarayanan R, Nair PP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis [J]. Nutr Cancer, 1995, 24(2): 197-202.
[22] Shetty P, Shenai P, Chatra L, et al. Efficacy of spiru-lina as an antioxidant adjuvant to corticosteroid injection in management of oral submucous fibrosis [J]. Indian J Dent Res, 2013, 24(3):347-350.
[23] Patil S, Halgatti V, Maheshwari S, et al. Comparative study of the efficacy of herbal antioxdants oxitard and aloe vera in the treatment of oral submucous fibrosis[J]. J Clin Exp Dent, 2014, 6(3):e265-e270.
[24] 李新民, 唐杰清. 茶色素治疗口腔粘膜下纤维性变的临床观察[J]. 华西口腔医学杂志, 1998, 16(1):50- 52.
Li XM, Tang JQ. Clinical treatment observation of tea pigment for oral submucous fibrosis[J]. West Chin J Stomatol, 1998, 16(1):50-52.
[25] Gupta D, Sharma SC. Oral submucous fibrosis—a new treatment regimen[J]. J Oral Maxillofac Surg, 1988, 46(10):830-833.
[26] Jiang XW, Zhang Y, Yang SK, et al. Efficacy of salvianolic acid B combined with triamcinolone ace-tonide in the treatment of oral submucous fibrosis[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(3):339-344.
[27] Alok A, Singh ID, Singh S, et al. Curcumin-pharma-cological actions and its role in oral submucous fib-rosis: a review[J]. J Clin Diagn Res, 2015, 9(10):ZE01-ZE03.
[28] Rai B, Kaur J, Jacobs R, et al. Possible action me-chanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress[J]. J Oral Sci, 2010, 52(2):251-256.
[29] Joshi J, Ghaisas S, Vaidya A, et al. Early human safety study of turmeric oil(Curcuma longa oil) administered orally in healthy volunteers[J]. J Assoc Physicians India, 2003, 51:1055-1060.
[30] Ramadass T, Manokaran G, Pushpala SM, et al. Oral submucous fibrosis-New dimensions in surgery[J]. Indian J Otolaryngol Head Neck Surg, 2005, 57(2): 99-102.
[31] Sudarshan R, Annigeri RG, Vijayabala GS. Aloe vera in the treatment for oral submucous fibrosis-a preliminary study[J]. J Oral Pathol Med, 2012, 41(10):755-761.
[32] Anil S, Beena VT. Oral submucous fibrosis in a 12-year-old girl: case report[J]. Pediatr Dent, 1993, 15(2):120-122.
[33] Katharia SK, Singh SP, Kulshreshtha VK. The effects of placenta extract in management of oral submucous fibrosis[J]. Indian J Pharmacol, 1992, 24(3):181-183.
[1] 张敏,万浩元. 种植体周围炎药物治疗与激光治疗的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 463-470.
[2] 吴秋月,李治邦. 药物辅助治疗种植体周围炎的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 471-477.
[3] 周婷茹,李永生. 牙髓干细胞成骨微环境的研究进展[J]. 国际口腔医学杂志, 2019, 46(6): 675-679.
[4] 程国平,丁一,郭淑娟. 静电纺丝纤维作为牙周药物传递系统的研究进展[J]. 国际口腔医学杂志, 2019, 46(5): 565-570.
[5] 叶畅畅, 赵蕾, 王冬青, 王晓丽, 王海燕, 游梦, 黄萍, 吴亚菲. 妊娠期牙周疾病的防治策略[J]. 国际口腔医学杂志, 2018, 45(5): 501-508.
[6] 吉宁, 赵行, 曾昕, 陈谦明. 核苷类抗疱疹病毒药物的研究进展[J]. 国际口腔医学杂志, 2018, 45(3): 351-357.
[7] 张艺馨, 李磊. 磷酸钙支架-药物缓释体系在骨组织工程中的研究进展[J]. 国际口腔医学杂志, 2018, 45(3): 346-350.
[8] 肖妍荻, 杨华梅, 但红霞. 抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策[J]. 国际口腔医学杂志, 2018, 45(2): 140-144.
[9] 詹烨明, 张明珠. 药物性牙龈增生与细胞增殖和凋亡相关性的研究进展[J]. 国际口腔医学杂志, 2018, 45(2): 199-203.
[10] 王智. 系统性疾病唇部损害的诊断及临床处理[J]. 国际口腔医学杂志, 2018, 45(2): 125-131.
[11] 王婷, 葛少华. 氧化石墨烯在生物医学领域方面应用的研究进展[J]. 国际口腔医学杂志, 2017, 44(5): 591-595.
[12] 李韶容, 张茹, 侯本祥. 根管用药对牙齿力学性能的影响[J]. 国际口腔医学杂志, 2017, 44(3): 273-278.
[13] 吕娇 赵文峰. 牙周病非手术治疗的研究进展[J]. 国际口腔医学杂志, 2016, 43(5): 594-598.
[14] 宋韬,王冏珂,文静,陈谦明,曾昕. 沙利度胺在口腔黏膜病临床治疗实践中的安全性分析[J]. 国际口腔医学杂志, 2016, 43(3): 366-370.
[15] 向臻婷 郑晓辉. 药物局部注射治疗原发性三叉神经痛的研究进展[J]. 国际口腔医学杂志, 2016, 43(1): 38-.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张京剧. 青年期至中年期颅面复合体变化的头影测量研究[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 刘玲. 镍铬合金中铍对可铸造性和陶瓷金属结合力的影响[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 王昆润. 在种植体上制作固定义齿以后下颌骨密度的动态变化[J]. 国际口腔医学杂志, 1999, 26(06): .
[4] 王昆润. 重型颌面部炎症死亡和康复病例的实验室检查指标比较[J]. 国际口腔医学杂志, 1999, 26(06): .
[5] 逄键梁. 两例外胚层发育不良儿童骨内植入种植体后牙槽骨生长情况[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 温秀杰. 氟化物对牙本质脱矿抑制作用的体外实验研究[J]. 国际口腔医学杂志, 1999, 26(05): .
[7] 杨春惠. 耳颞神经在颞颌关节周围的分布[J]. 国际口腔医学杂志, 1999, 26(04): .
[8] 王昆润. 牙周炎加重期应选用何种抗生素[J]. 国际口腔医学杂志, 1999, 26(04): .
[9] 杨儒壮 孙宏晨 欧阳喈. 纳米级高分子支架材料在组织工程中的研究进展[J]. 国际口腔医学杂志, 2004, 31(02): 126 -128 .
[10] 严超然,李龙江. 肿瘤靶向药物载体系统的研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .